Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 12, 2026

Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million?

CEO Christopher Anzalone sold 85,000 shares in the open market on Dec. 17, 2025, for a transaction value of ~$5,443,462. This sale represented 2.17% of Mr.

The Motley Fool • Jan 11, 2026

Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Chinese National Medical Products Administration (NMPA) has approved REDEMPLO® (plozasiran) for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS). FCS is a severe, rare disease characterized by triglyceride levels that can be 10 to 100 times higher than normal leading to a substantially higher risk of developing acute, recurrent, and potent.

Business Wire • Jan 7, 2026

Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of common stock, at a public offering price of $64.50 per share (or, in lieu of shares of common stock to certain investors, pre-funded warrants, at a public offering price of $64.499 per pre-funded warrant, for up to 1,550,.

Business Wire • Jan 8, 2026

Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide.

Investors Business Daily • Jan 6, 2026

Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials

Arrowhead, Inc. (NASDAQ: ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics for obesity.

Benzinga • Jan 6, 2026

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript

Seeking Alpha • Jan 6, 2026

Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company's investigational RNA interference (RNAi) therapeutics being developed as potential treatments for obesity. Preliminary results with Arrowhead's promising new approach to treating obesity and metabolic diseases showed meaningful reductions in multiple key measures, including visceral fat, total fat, and liver.

Business Wire • Jan 6, 2026

Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to grant the underwriters of the note offering a 30-day option to purchase up to an additional $75 milli.

Business Wire • Jan 6, 2026

Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update

Arrowhead Pharmaceuticals, Inc. shares rose on early data from obesity candidates ARO-INHBE and ARO-ALK7, but I have more questions than answers. INHBE-targeted monotherapy is unlikely to drive meaningful weight loss. Combination data with tirzepatide showed promising weight loss, but tiny sample sizes and missing datasets raise concerns about the true efficacy.

Seeking Alpha • Jan 6, 2026